BGLC BioNexus Gene Lab Corporation

BioNexus Gene Lab Corporation, a molecular diagnostics company, develops and commercializes molecular diagnostic tests for the early detection of diseases and personalized health management, primarily focusing on cardiovascular, diabetes, and cancer-related indications primarily in Malaysia. Its non-invasive blood tests are used to analyze changes in ribonucleic acid for the detection of cancers, including nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon; bowel diseases, such as colitis and Crohn; and osteoarthritis. The company markets its blood screening process to health care providers, such as doctors, laboratories, and hospitals. BioNexus Gene Lab Corporation was founded in 2017 and is based in Kuala Lumpur, Malaysia.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$2.13    OTCQB
As of 01/14/2022     OTCMarkets


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Unknown
Industry:  Diagnostics & Research
Index country:  Malaysia
Country of incorporation:  
IPO date:  12/24/2020
Outstanding shares:  171,218,152
Average volume:  415
Market cap:   $364,694,664
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   188.88
PB ratio:   51.95
PS ratio:   16.85
Return on equity:   27.38%
Net income %:   8.92%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy